Accelerated Clinical Path
Prior human exposure to cethromycin base supports a rapid path toward clinical proof-of-concept.
Liver-Stage Focus
Development is centered on dormant liver-stage malaria and relapse prevention.
Short-Course Design
The program is designed around short, exposure-bounded treatment courses.
Beyond Malaria
Following human proof-of-concept in malaria, Cethromycin HCl may support additional infectious disease opportunities.
David Sullivan, MD
Co-Founder, Chief Scientific Officer, Chair of the Board
Physician-scientist and professor at the Johns Hopkins Bloomberg School of Public Health with more than 30 years of experience in malaria research and clinical infectious diseases.
Nikola Kaludov, PhD
Co-Founder, President, Board Member
Biotechnology scientist and entrepreneur with extensive experience in translational drug development, IP strategy, and capital-efficient execution through IND readiness and partnering.
Gaurav Vij
Strategic Advisor
Biopharma BD executive with extensive experience leading global licensing, M&A, and strategic partnerships across major pharmaceutical companies including Gilead, Amgen, & Shire.
Amy Tapper, PhD
CMC/Advisor
Chemist with over 20 years of experience in drug discovery and development, with deep expertise in CMC strategy for emerging biotech companies.
Fredric D. Abramson, PhD, JD
Legal Advisor, Board Member
Attorney with decades of experience in patents, trademarks, and intellectual property strategy.
Steen Nissen, MSc, MBA
Executive Director
Global business executive with experience across life sciences, energy, and international operations.